Celsion to Present at the Rodman & Renshaw Global Investment Conference
LAWRENCEVILLE, N.J., Sept. 6, 2013 /PRNewswire/ -- Celsion Corporation (Nasdaq: CLSN), a leading oncology drug development company, today announced that Michael H. Tardugno, Celsion's President and Chief Executive Officer, will present at the Rodman & Renshaw Global Investment Conference on Monday, September 9, 2013 at 11:40 a.m. Eastern time. The conference is being held at the Millennium Broadway Hotel in New York City. The investor presentation will be available on Celsion's website at http://investor.celsion.com/events.cfm.
About the Rodman & Renshaw Global Investment Conference
The 2013 Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, will be held in New York City from September 8 – 10, 2013 at The Millennium Broadway Hotel. More than 200 public and private companies from around the world are expected to present to an audience of over 1,500 attendees. The conference will feature tracks devoted to Biotechnology/Healthcare, Technology, Natural Resources and Growth.
About Celsion Corporation
Celsion is dedicated to transforming the landscape of treating cancer by utilizing innovative targeting technologies, including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license or commercialization agreements with leading institutions, including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford. For more information on Celsion, visit our website: http://www.celsion.com.
Jeffrey W. Church
Senior Vice President and
Chief Financial Officer
SOURCE Celsion Corporation
More by this Source
Celsion Announces Positive Interim Data from Phase 2 DIGNITY Trial in Breast Cancer
Feb 27, 2014, 16:05 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.